(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8...
Stats | |
---|---|
今日成交量 | 1.46M |
平均成交量 | 798 146 |
市值 | 65.08M |
EPS | $0 ( 2024-05-02 ) |
下一个收益日期 | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.686 |
ATR14 | $0.0570 (5.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-08 | Sigal Charles Elliott | Sell | 45 453 | Common Stock |
2023-09-08 | Sigal Charles Elliott | Sell | 113 636 | Stock Option (Right to Buy) |
2023-09-08 | Adams Chandra | Sell | 23 884 | Common Stock |
2023-09-08 | Adams Chandra | Sell | 50 000 | Stock Option (Right to Buy) |
2023-09-08 | Rath Henry C. | Sell | 44 971 | Common Stock |
INSIDER POWER |
---|
-73.79 |
Last 94 transactions |
Buy: 4 462 585 | Sell: 5 534 482 |
音量 相关性
Surface Oncology Inc 相关性 - 货币/商品
Surface Oncology Inc 财务报表
Annual | 2022 |
营收: | $30.00M |
毛利润: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2022 |
营收: | $30.00M |
毛利润: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2021 |
营收: | $2.69M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.735 |
FY | 2020 |
营收: | $126.16M |
毛利润: | $0.00 (0.00 %) |
EPS: | $1.670 |
Financial Reports:
No articles found.
Surface Oncology Inc
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。